Green, Claire  ORCID: https://orcid.org/0000-0003-0483-1197, Evans, Catherine M., Zhao, Lu, Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E.
2011.
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
Blood
118
(2)
, pp. 409-412.
10.1182/blood-2010-12-322479
|
Abstract
We have investigated the prognostic significance of isocitrate dehydrogenase 2 (IDH2) mutations in 1473 younger adult acute myeloid leukemia patients treated in 2 United Kingdom Medical Research Council trials. An IDH2 mutation was present in 148 cases (10%), 80% at R140 and 20% at R172. Patient characteristics and outcome differed markedly between the 2 mutations. IDH2R140 significantly correlated with nucleophosmin mutations (NPM1MUT), whereas IDH2R172 cases generally lacked other molecular mutations. An IDH2R140 mutation was an independent favorable prognostic factor for relapse (P = .004) and overall survival (P = .008), and there was no significant heterogeneity with regard to NPM1 or FLT3 internal tandem duplication (FLT3/ITD) genotype. Relapse in FLT3/ITDWTNPM1MUTIDH2R140 patients was lower than in favorable-risk cytogenetics patients in the same cohort (20% and 38% at 5 years, respectively). The presence of an IDH2R172 mutation was associated with a significantly worse outcome than IDH2R140, and relapse in FLT3/ITDWTNPM1WTIDH2R172 patients was comparable with adverse-risk cytogenetics patients (76% and 72%, respectively).
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Medicine |
| Subjects: | R Medicine > R Medicine (General) |
| Publisher: | American Society of Hematology |
| ISSN: | 0006-4971 |
| Last Modified: | 06 Nov 2024 22:22 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/28377 |
Citation Data
Cited 223 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric